AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Pelthos Therapeutics Drops 1.35% Amid NYSE Listing
Generated by AI AgentAinvest Pre-Market Radar
Tuesday, Jul 8, 2025 7:17 am ET1min read
On July 8, 2025,
experienced a 1.35% drop in pre-market trading, reflecting a slight decline in investor sentiment.Pelthos Therapeutics, a clinical-stage biotechnology company, has been focusing on developing novel, non-opioid, non-addictive therapeutics to alleviate pain. The company's initial clinical focus is on selectively targeting the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks.
Recently, Pelthos Therapeutics announced that it will begin trading on the NYSE American under the ticker symbol 'PTHS' starting July 2, 2025. This move is part of the company's strategic efforts to enhance its market presence and accessibility to a broader range of investors.
Additionally, there have been significant insider activities within the company. Director Richard Malamut was granted 19,108 Restricted Stock Units (RSUs) and 58,230 options at a strike price of $13.50. These equity awards are set to vest over a period of three years, indicating a long-term commitment from the company's leadership.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
SEALSQ Surged 8.29% Driven by 2026–2030 Roadmap for Silicon-Based Quantum Computing Systems
Dec.19 2025
Serve Robotics (SERV) Surges 5.97% on Bullish Oppenheimer Note
Dec.19 2025
AXT Inc. shares surge 13.35% on renewed earnings upside speculation amid supply chain adjustments
Dec.19 2025
PROK surged 5.11% on Dec. 19 2025 after HC Wainwright upgraded to Buy rating
Dec.19 2025
Tesla shares surge 3.45% as SpaceX orders 1,000-2,000 Cybertrucks for Starbase facility.
Dec.19 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet